series-c-plus
Stage
4
Investors
About
Orum Therapeutics is a clinical-stage biotech company developing a novel class of Antibody Degrader Conjugates (ADCs) using protein degrader technology for improved efficacy and safety in treating diseases such as acute myeloid leukemia (AML).
Explore Orum Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.